Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Download this page as JSON

Period	Milestone	Group	Participants
Induction Phase	STARTED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	28
Induction Phase	STARTED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	44
Induction Phase	COMPLETED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	27
Induction Phase	COMPLETED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	42
Induction Phase	NOT COMPLETED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	1
Induction Phase	NOT COMPLETED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	2
Consolidation Phase	STARTED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	22
Consolidation Phase	STARTED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	32
Consolidation Phase	COMPLETED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	22
Consolidation Phase	COMPLETED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	32
Consolidation Phase	NOT COMPLETED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	0
Consolidation Phase	NOT COMPLETED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	0
Intensification Phase	STARTED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	6
Intensification Phase	STARTED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	11
Intensification Phase	COMPLETED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	5
Intensification Phase	COMPLETED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	11
Intensification Phase	NOT COMPLETED	Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse	1
Intensification Phase	NOT COMPLETED	Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02927769/flow

API reference For AI assistants